Results 141 to 150 of about 216,058 (206)

Polyfunctional CD8+CD226+RUNX2hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia

open access: yesMolecular Oncology, Volume 19, Issue 5, Page 1347-1370, May 2025.
CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar   +4 more
wiley   +1 more source

Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinoma

open access: yesThe Journal of Pathology: Clinical Research, Volume 11, Issue 3, May 2025.
Abstract Ductal adenocarcinoma of the prostate (DA) is relatively rare and highly co‐existent with prostate adenocarcinoma (AC). This study aimed to investigate the distinctive genomic profiles of patients with DA compared to those without. Blood samples were obtained from 144 patients (36 with DA and 108 without DA) who were diagnosed from 2017 to ...
Qiyu Zhu   +14 more
wiley   +1 more source

NF2 is Essential for Human Endoderm Development

open access: yesAdvanced Science, Volume 12, Issue 17, May 8, 2025.
This study demonstrates that NF2, moesin‐ezrin‐radixin like (MERLIN) tumor suppressor (NF2) is essential for human endoderm formation. NF2 knockout human induced pluripotent stem cells fail to form endoderm both in vitro and in vivo due to yes‐associated protein 1 (YAP1) nuclear translocation, redirecting differentiation toward myofibroblast‐like cells.
Minjin Jeong   +5 more
wiley   +1 more source

Breaking barriers: Smart vaccine platforms for cancer immunomodulation

open access: yesCancer Communications, Volume 45, Issue 5, Page 529-571, May 2025.
Abstract Despite significant advancements in cancer treatment, current therapies often fail to completely eradicate malignant cells. This shortfall underscores the urgent need to explore alternative approaches such as cancer vaccines. Leveraging the immune system's natural ability to target and kill cancer cells holds great therapeutic potential ...
Mohammad Mahmoudi Gomari   +11 more
wiley   +1 more source

Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunities

open access: yesCancer Communications, Volume 45, Issue 5, Page 577-607, May 2025.
Abstract Copper, one of the essential nutrients for the human body, acts as an electron relay in multiple pathways due to its redox properties. Both deficiencies and excesses of copper lead to cellular fragility. Therefore, it can manifest pro‐ and anti‐cancer properties in tumors. Therefore, it is crucial to clarify the copper activity within the cell.
Dan Shan   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy